Kornimate/medical-research-clean huggingface dataset:
the effect of astarte™ on recurrent urinary tract infection

Conditions: Recurrent Urinary Tract Infection

Summary: investigate the effect of dietary supplements/probiotic astarte™ ( l. crispatus, l. rhamnosus, l. jensenii, l. gasseri) on the microbiome composition in the intestine and vagina and thereby a reduction of risk factors for the development of ruti during 6 months of intervention in women aged 18-40 years. this is measured by the incidence of symptomatic uti.

urinary tract infection (uti) is one of the most common infections, contributing to increased antibiotic consumption and high costs. women are often developing uti due to the anatomically short distance from the rectum opening to the urethra. there is a risk of serious complications associated with pregnancy, where there is an increased risk of developing pelvic inflammatory disease and premature birth. this will in some cases lead to increased risk of maternal and neonatal morbidity and mortality; especially in infection with streptococcus agalactiae. recurrent uti (ruti) with urease producing microorganisms such as proteus and klebsiella will cause an increased risk of developing stones in the urinary tract. scientific studies suggest that probiotics can be effective dietary supplements reducing the risk factors for the development of infections in the intestine and vagina. probiotics are non-pathogenic microorganisms capable of affecting gastrointestinal microbiota with a change in microbiota composition, thus increasing the production of beneficial substances when ingested in appropriate quantities. the consumption of probiotics is not considered to be associated with adverse reactions to humans because they are usually found naturally in e.g. gastrointestinal and vaginal microbiota. a prospective study over 2-years which is conducted as a randomized placebo-controlled double-blind study. in this study the investigators will investigate the effect of probiotics astarte™ ( lactobacillus crispatus, lactobacillus rhamnosus, lactobacillus jensenii, lactobacillus gasseri) on the composition of bacteria in urine, faces and vagina, and a possible reduction of risk factors for development of ruti in women (18 to 40 years). the investigators will map the microbiota in the faeces and vagina and examine if there are a relationship between colonization of the urinary tract with pathogens and the composition of the intestinal and vaginal microbiota.

Eligibility criteria:
inclusion criteria: * women 18-40 years of age * recurrent uti (2 times uti within 6 months or \> 3 times uti infection within one year). * the subjects should be informed about the trial protocol. * the subject must be able to follow the protocol, have provided voluntary consent and have signed the declaration of consent. exclusion criteria: * pregnancy or planning pregnancy * breastfeeding * participation in another trial with probiotic the last 30 days. * hypersensitivity to any ingredient in the study product * patients primarily admitted for a disorder other than uti * antibiotic treatment for any other condition than uti at time of recruitment the last 30 days

Keywords: ruti probiotic
prospective comparative study evaluating the early complications of robot-assisted radical prostatectomy performed as an outpatient versus an inpatient procedure.

Conditions: Prostate Cancer Surgery; Ambulatory Care; Outpatient Surgery

Summary: the goal of this clinical trial is to demonstrate that outpatient management for robotic-assisted radical prostatectomy is not inferior to inpatient management in terms of the occurrence of early post-operative complications. researchers will compare outpatient robot-assisted radical prostatectomy to inpatient procedure. participants will: * visit the clinic after the operation once at 45 days, 6 months and once a year for up to 5 years for check-ups and tests. * answer survey questions about urinary and erectil functions, stress and anxiety, satisfaction, quality of life for 6 months * keep a diary to record procedures and treatments related to the care provided


Eligibility criteria:
inclusion criteria: * male, aged 18 and over * patient with prostate cancer for which the multidisciplinary meeting has proposed radical prostatectomy as a therapeutic option (with or without lymphadenectomy) * patient eligible for outpatient treatment : 1. the patient undertakes to comply with all medical instructions given during surgical consultations and the anaesthetic consultation. 2. the patient has access to personal transport allowing, if necessary, return to the facility or another approved facility (transport time and distance from the facility are not exclusion factors) 3. the patient has access to telephone communication facilities. 4. the patient undertakes not to drive a vehicle and to be accompanied on his return home and for the next 24 hours by a responsible person who will be familiar with the monitoring instructions. 5. the patient plans to remain in hospital overnight if this is deemed necessary by the department's doctors (operator and anaesthetist). the patient accepts this mode of care and its constraints. * participant affiliated to or benefiting from a social security scheme * the participant has been informed and has given his/her free, informed and written consent (at the latest on the day of inclusion and before any examination required by the research). exclusion criteria: * patient already treated for prostatic carcinoma with brachytherapy, radiotherapy or focal therapy * patient participating in ongoing research or in a period of exclusion at the time of inclusion * refusal or inability to comply with the study protocol for any reason whatsoever * protected participant: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.
the exploreration of the management for the positive iaa in patients with type 2 diabetes after premix insulin therapy

Conditions: Type 2 Diabetes Mellitus

Summary: premix insulin is widely used, with high proportion of positive insulin autoimmune antibody in patients with type 2 diabetes. the positive insulin autoimmune antibody may affect blood glucose control. we aim to explore the management for the positive insulin autoimmune antibody and blood glucose control in these patients, and investigate the immune cells changes with the change of different glucose lowering drugs.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes; * treated with premix insulin, two or three injections a day, single drug or combination of oral hypoglycemic drugs; * the treatment regimen was stable for more than 2 months; * with positive insulin antibody exclusion criteria: * patients treated with glp-1 agonist in the last 3 months; * allergic to insulin; * impaired liver and renal function (alt 2.5 times higher than the upper limit of normal value; serum creatinine was 1.3 times higher than the upper limit of normal); * a history of drug abuse and alcohol dependence; * used systemic glucocorticoids therapy in recent 3 months; * patients with infection or stress within four weeks; * patients who cannot tolerate fgm; * pregnant or preparing to become pregnant; * considered unsuitable to participate by the investigator.
avadeno study: an observational study of first-line avastin (bevacizumab) in patients with adenocarcinoma of the lung

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this prospective observational study will evaluate the efficacy and safety of first-line avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (\ 80 years) in patients with inoperable advanced, metastatic or recurrent adenocarcinoma non-small cell lung cancer. patients will be followed for 18 months from the start of first-line therapy.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * histologically confirmed inoperable advanced, metastatic or recurrent pre-dominantly non-squamous adenocarcinoma non-small cell lung cancer exclusion criteria: * contraindications to avastin treatment according to the summary of product characteristics
heart attack research program: platelet sub-study (harp)

Conditions: Myocardial Infarction

Summary: this prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (minoca or mi-cad) and controls. this study, which will take place at nyu and bellevue medical center, and participating external sites. may have concurrent enrollment with the harp main imaging (nct02914483). additionally, a sex, group of age and race matched disease controls 'cath-noca' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. blood obtained during the initial catheterization and 2 months post-mi will be utilized for platelet testing.


Eligibility criteria:
inclusion criteria: * acute ischemic symptoms compatible with diagnosis of mi, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms * objective evidence of mi (either or both of the following): * elevation of troponin to above the laboratory upper limit of normal (uln) * st segment elevation of ≥1mm on 2 contiguous ecg leads * willing to provide informed consent and comply with all aspects of the protocol * administration of aspirin at least 1 hour before cardiac catheterization * administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization * women and men with ≥50% of any major epicardial vessel on invasive angiography may participate exclusion criteria: * recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month) * alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma * pregnancy * thrombolytic therapy for stemi (qualifying event) * use of any of the following medications: * platelet antagonists (except aspirin and thienopyridines) within 7 days * nsaids (e.g., ibuprofen, naproxen) within 3 days. * thrombocytopenia (platelet count \<100,000) * thrombocytosis (platelet count \>500,000) * anemia (hemoglobin \<9 mg/dl) * hemorrhagic diathesis

Keywords: myocardial infarction platelets blood collection genomics
efficacy of non-invasive mechanical ventilation in early hypoxia secondary to thoracic trauma

Conditions: Post-Traumatic Respiratory Failure

Summary: * severe post-traumatic hypoxia is mainly due to lung contusion. the intubation rate of these patients is near 20%. * treatment before intubation is needed, is based on pain control with epidural anesthesia and oxygen. * the investigators' hypothesis is that adding non-invasive mechanical ventilation to the standard treatment can reduce the intubation rate if applied early in the course of the disease. * as thoracic trauma is often associated with injuries in other body regions that may increase the complications of the technique, specific contraindications have been described.


Eligibility criteria:
inclusion criteria: * age \> 18 years. * informed consent obtained. * po2/fio2 \<200 for more than 8 consecutive hours in the first 48 hours after thoracic trauma. exclusion criteria: * orotracheal intubation indicated for any other reason. * standard contraindication for non-invasive ventilation (active gastro-intestinal haemorrhage, low level of consciousness, multiorgan failure, airway control problems, lack of cooperation, hemodynamic instability). * severe traumatic brain injury. * facial trauma with pneumocephalus, skull base fracture, orbit base fracture, any facial fracture involving a sinus. * cervical injury with specific treatment contraindicating a facial mask. * bronco-pleural fistula. * gastro-intestinal trauma.
verbal working memory and attention remediation for adults with traumatic brain injury.

Conditions: Traumatic Brain Injury

Summary: this project will examine if computerized cognitive remediation will improve working memory and attention in 25 adults with a mild, moderate, or severe brain injury and compare their cognitive performance to the control group of 25 adults with a mild, moderate, or severe brain injury. the control group will train on computerized tasks of social awareness. participants in both groups will be assessed prior to training and immediately post-training and one month-post training.

the study design will be randomized assignment with a control group. participants in both groups will undergo three cognitive assessments at baseline, at the end of 40 cognitive training modules, and 1-month post-completion of the first follow-up assessment.

Eligibility criteria:
inclusion criteria: * medically documented mild, moderate, or severe tbi; * all subjects will be older than 18 years of age; * free from schizophrenia or bipolar disorder, due to the potential influence of such disorders on cognitive functioning; * free of current alcohol or drug abuse; * at least 3 months post-injury. exclusion criteria: * younger than 18 years old. * a brain injury that is not medically documented. * being diagnosed with schizophrenia or bipolar disorder. * current alcohol or drug use diagnosis * less than 3 months post-injury
safety, tolerability and performance of smartmatrix dermal replacement scaffold

Conditions: Basal Cell Carcinoma; Squamous Cell Carcinoma

Summary: smartmatrix™ is a single layer dermal replacement scaffold for full thickness skin replacement. the scaffold consists of a porous matrix of cross-linked human fibrin plus alginate that has been designed and optimised to facilitate wound closure and healing through cellular ingress and rapid growth of new blood vessels. this proof of concept study will involve patients with surgical wounds resulting from the excision of basal cell carcinoma (bcc) and squamous cell carcinoma scc).


Eligibility criteria:
inclusion criteria: * male or female, at least 18 years of age * suspected or histologically proven bcc or scc * suspected or histologically proven bcc or scc ≥1cm ≤3cm in diameter on either leg * expected defect following surgery ≥3cm, ≤6cm in diameter * patient or authorised representative able to comprehend and sign the informed consent prior to enrolment in the study exclusion criteria: * aged \<18 years of age * pregnant or lactating females * skin lesion \>4cm in diameter or size that will result in post-surgical defect \>6cm in diameter * lesion located over joint, i.e. ankle or knee * patient who are smokers * diabetic patients * patients diagnosed with peripheral vascular disease or venous stasis * patients receiving regular systemic steroids * patients who are immuno-compromised (either acquired or congenital) * patients with a known coagulopathy (either acquired or congenital) but not including patients on aspirin or other anti-platelet therapy * patients who have received radiotherapy treatment to the area about to be treated with smart matrix * concurrent participation in another experimental intervention or drug study * unwilling or unable to provide informed consent
effect of upper extremity rehabilitation using immersive virtual reality in chronic stroke patients.

Conditions: Stroke

Summary: the study aimed to investigate the effect of exergames using virtual reality with head mounted device on motor recovery of upper extremities in chronic stroke patients.

this is a crossover study for comparing conventional occupational therapy and exercise with game format using virtual reality (virtual reality exergame). the virtual reality exergame is designed to maximize the movement of upper extremities, primary to the shoulder and elbow. fifteen chronic stroke patient will receive conventional occupational treatment and virtual reality exergame in random order with a two-week-washout period. outcome measures will be evaluated within two days before and after each treatment, conventional treatment and virtual reality exergame. \*due to recruitment challenges, the anticipated enrollment has been revised from 36 to 15.

Eligibility criteria:
inclusion criteria: * chronic stroke patients who have passed 6 months or more without additional stroke after the first stroke * patients with upper extremity dysfunction due to stroke (ischemic, hemorrhagic) * patients who can move the upper extremity against gravity with a manual muscle test of grade 3 or higher in the affected shoulder and elbow, respectively * patients who can stably maintain a sitting position * patients who voluntarily agreed to participate in the study exclusion criteria: * patients with moderate or severe cognitive impairment with a score of 18 or less on the mini-mental status examination (k-mmse) * patients with other causes of upper extremity dysfunction, such as peripheral nerve damage, joint disease, etc. * patients with a history of severe vertigo or epilepsy * patients with medical reasons such as medical conditions that make it difficult to participate in research * patients who may be pregnant or who are pregnant or lactating

Keywords: stroke virtual reality upper extremity paresis
glaucoma after congenital cataract surgery

Conditions: Glaucoma; Congenital Cataract

Summary: to determine the incidence of glaucoma following bilateral congenital cataract removal and estimate the associated risk factors in a large cohort to provide guidance for clinical practice.

a prospective longitudinal cohort study of pediatric patients who underwent surgery for congenital/infantile cataracts between january 2011 and december 2025 was performed.

Eligibility criteria:
inclusion criteria: * a diagnosis of bilateral congenital cataracts, the etiologies include congenital idiopathic cataract and congenital cataract associated with a systemic syndrome or ocular anomalies; * cataract surgery performed in zoc; * age at cataract removal younger than 16 years; exclusion criteria: * the preoperative iop was above 21 mm hg; * family history of glaucoma; * signs of preoperative glaucoma were present, such as corneal clouding, corneal enlargement, excessive cup-disc ratio and myopic shift; * ocular trauma history; * previous surgery intervention and * they were noncompliant with our follow-up protocol to monitor the occurrence of glaucoma and glaucoma suspect.
frailty status and quality of life in elderly

Conditions: Frailty; Quality of Life

Summary: frailty is a dynamic process from fit (robust) and pre-frail elderly. there is no previous study that determine the risk factors from fit to pre-frailty and pre-frailty to frailty in indonesian elderly. this study was aimed to define the risk factors of frailty transitional status and its correlation with quality of life in indonesian elderly outpatients.

frailty is an age-associated, biological syndrome characterized by decreased biological reserves, due to dysregulation of several physiological systems, which puts an individual at risk when facing minor stressors, and is associated with poor outcomes (ie, disability, death, and hospitalization). frailty identifies a high-risk subgroup and off ers characteristics of great clinical importance: a higher reversibility at early stages than disability, and a higher predictive value than chronic disease for adverse outcomes at older ages. it is also the most common condition leading to death in community-dwelling older people. however, there is current consensus that physical frailty is potentially reversible. it is hence useful to objectively detect frailty among frail elderly persons, as frailty indices serve a useful purpose for risk stratification, predicting need for institutional care and planning of services needed. to date, there is no study or information about frailty status in indonesia elderly. this study was aimed to define the risk factors of frailty transitional status and its correlation with quality of life in indonesian elderly.

Eligibility criteria:
inclusion criteria: 1. elderly aged \>= 60 years old 2. fit (robust) or pre-frailty; 3. capable to understand and carry-out the instruction. exclusion criteria: 1. unwilling to join the study; 2. abbreviated mental test (amt) score \< 8; 3. geriatric depression scale (gds) score \>= 10; 4. body mass index (bmi) \<18,5 kg/m2; 5. malnutrition (according to mini nutritional assessment/mna); 6. liver cirrhosis, severe liver dysfunction, or serum alt levels \>3 times upper normal limit; 7. acute illness during inclusion period, eg. pneumonia, pain due to acute arthritis (visual analog scale \>6/10), stroke attack, crisis hypertension; 8. severe cardiac dysfunction: acute decompensated heart failure and/or chronic heart failure functional class iii or iv (new york heart association classification); 9. severe pulmonary dysfunction: acute exacerbation of chronic obstructive lung disease stage iii or iv (gold classification), and/or pao2 levels \< 60 mmhg.

Keywords: frailty pre-frailty fit robust elderly sociodemography status functional status cognitive status nutrition status comorbidity mortality depression status
mindspeed food and brain training rct

Conditions: Low Education; Cognition; Cognitive Training; Polyphenols

Summary: the purpose of this study is to learn how foods high in polyphenols and brain training exercises affect older adults' cognitive performance

adults with low education who give informed consent will complete a baseline cognitive assessment and then be randomized to one of four arms: 1) mind foods and cognitive training, 2) mind foods and control training, 3) control foods and cognitive training, or 4) control foods and control training. all interventions are conducted through applications running on a tablet computer device that we will provide to all participants for the study duration. cognitive training is delivered through the online brainhq program from posit science, inc. the foods will be shown on the tablet device in an online shopping format. selected foods will be prepared and delivered by the study team. active intervention will last for 12 weeks. after the 12-weeks, free food deliveries will cease but participants who were allocated to cognitive training will continue to have access to brainhq. those in the mind food arms will be encouraged to maintain mind food consumption.

Eligibility criteria:
inclusion criteria: * age 60 years or older, * ≤ 12 years of education, * english speaking, * marion county (and immediately surrounding counties) resident, with steady/fixed residence to receive food deliveries * natural-born us citizen. exclusion criteria: * living in nursing home * self-reported diagnosis of dementia, alzheimer's disease (ad), cancer with short life expectancy, multiple sclerosis, epilepsy, schizophrenia, bipolar disorder, parkinson disease; current chemotherapy or radiation therapy; history of brain tumor, brain surgery, brain infection; stroke or myocardial infarction within the past 12 months * current alcohol consumption ≥8 drinks per week for women or ≥15 drinks per week for men; * poor vision (self-reported difficulty reading a newspaper) or color blind; * low communicative ability (examiner rated) that would interfere with interventions and assessments; * prior involvement in similar cognitive training studies; * unable or unwilling to provide blood sample at baseline * tumor, hemorrhage, aneurysm, hydrocephalus, or other significant clinical finding from baseline brain mri

Keywords: randomized controlled trial cognition cognitive training mind diet quality of life alzheimer's disease